UNI-EN 109:Current report 109- 01.11.2012 EGM ENG
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 109 | / | 2012 | | ||||||
| Date of issue: | 2012-11-02 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Current report 109- 01.11.2012 EGM ENG | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Pursuant to art. 117, par. 2 of the Public Offering of Securities Act and art. 27, par. 5 of Ordinance № 2/17.09.2003 on the prospectuses for public offerings of securities and disclosure of information by public companies and other issuers of securities, please be informed that the Extraordinary General Meeting of shareholders of Sopharma AD, held on 01.11.2012 in Sofia, 16 Iliensko shousee, took the following decision: - amended the conditions for share repurchase, determined by the decision taken on item 14 of the agenda of the regular AGM, held on 23 June 2010, and amended by the decision of the Extraordinary General Meeting of Shareholders from 30 November 2011, as follows: the repurchase of own shares representing the company’s capital, subject to the specific requirements of CA and POSA, shall be carried out under the following conditions: volume of treasury shares - up to 10% of the total number of shares issued by the company, but not more than 3% for one calendar year; period of execution of the repurchase – not longer than 5 (five) years; minimum repurchase price– 2.10 BGN; the maximum repurchase price of 5,50 BGN per share, determined by a decision of the regular AGM from 23 June 2010, shell not be amended | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 109- 01.11.2012 EGM ENG.doc Current report 109- 01.11.2012 EGM ENG.doc | Current report 109- 01.11.2012 EGM ENG | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2012-11-02 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
